Press Release: 6/30/2025

Brown Rudnick Advises Vor Bio in $125 million Global License Agreement with RemeGen for Ex-China Rights to Telitacicept

 

PUBLISHED ON: 06/27/2025

 

Brown Rudnick advised public company Vor Bio in its exclusive license agreement with RemeGen, a leading biopharmaceutical company in China, granting Vor Bio global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize Telitacicept, a novel dual-target fusion protein for generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. RemeGen is conducting a global Phase 3 clinical trial which is now enrolling in the United States, Europe, and South America, with initial results expected in the first half of 2027.

Under the agreement, Vor Bio will make a $125 million initial payment, with $45 million in upfront cash and $80 million in warrants. The agreement includes potential regulatory and commercial milestones exceeding $4 billion, in addition to tiered royalties.

The Brown Rudnick team representing Vor Bio on the license agreement was led by partner Elizabeth Parsons and included partners Adam Schoen, Dean Ramanathan and Peter Farrell, and associate Tamara Palmer.